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Abstract
The molecular triggers for axon degeneration remain unknown. We identify endogenous Nmnat2 as a labile axon survival
factor whose constant replenishment by anterograde axonal transport is a limiting factor for axon survival. Specific
depletion of Nmnat2 is sufficient to induce Wallerian-like degeneration of uninjured axons which endogenous Nmnat1 and
Nmnat3 cannot prevent. Nmnat2 is by far the most labile Nmnat isoform and is depleted in distal stumps of injured neurites
before Wallerian degeneration begins. Nmnat2 turnover is equally rapid in injured Wld
S neurites, despite delayed neurite
degeneration, showing it is not a consequence of degeneration and also that Wld
S does not stabilize Nmnat2. Depletion of
Nmnat2 below a threshold level is necessary for axon degeneration since exogenous Nmnat2 can protect injured neurites
when expressed at high enough levels to overcome its short half-life. Furthermore, proteasome inhibition slows both
Nmnat2 turnover and neurite degeneration. We conclude that endogenous Nmnat2 prevents spontaneous degeneration of
healthy axons and propose that, when present, the more long-lived, functionally related Wld
S protein substitutes for
Nmnat2 loss after axon injury. Endogenous Nmnat2 represents an exciting new therapeutic target for axonal disorders.
Citation: Gilley J, Coleman MP (2010) Endogenous Nmnat2 Is an Essential Survival Factor for Maintenance of Healthy Axons. PLoS Biol 8(1): e1000300.
doi:10.1371/journal.pbio.1000300
Academic Editor: Ben A. Barres, Stanford University School of Medicine
Received July 6, 2009; Accepted December 18, 2009; Published January 26, 2010
Copyright:  2010 Gilley, Coleman. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is funded by the United Kingdom Medical Research Council (MRC) Programme grant G0300408(http://www.mrc.ac.uk/). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors and host institution have a patent pending related to this work.
Abbreviations: CHX, cycloheximide; DRG, dorsal root ganglion; eGFP, enhanced green fluorescent protein; NF-H, neurofilament heavy chain; RT-PCR, Reverse
Transcriptase PCR; SCG, superior cervical ganglion
* E-mail: michael.coleman@bbsrc.ac.uk
Introduction
The endogenous molecular trigger for Wallerian degeneration
remains unknown. Recent progress towards understanding how
the slow Wallerian degeneration fusion protein (Wld
S) delays
degeneration of injured and sick axons has not addressed this
wider question [1–8], and this aberrant protein is only expressed in
a few strains of mouse, rat, and fly. Knowledge of the normal
regulation of axon survival in wild-type animals should not only
lead to greater mechanistic insight but could also have important
therapeutic implications for axon protection since pharmacolog-
ical manipulation of endogenous processes is likely to be more
achievable than overexpression of exogenous proteins.
Many stresses that induce Wallerian or Wallerian-like degen-
eration involve a partial or complete block of axonal transport.
Since transport is bi-directional, degeneration could be triggered
by failed anterograde delivery of essential survival factors or by
failed removal of harmful substances by retrograde transport.
Defective anterograde transport seems more directly associated
with axon loss than dysfunctional retrograde transport [9–13].
Therefore, extending an old model [14], we propose a ‘‘survival
factor delivery hypothesis’’ of axon degeneration. We suggest that
axon integrity requires continuous anterograde delivery of one or
more labile, cell body–synthesized survival factors. Other axonal
components should be dispensable, more long-lived, or synthe-
sized locally. Once supply is disrupted, following injury or other
insult, levels of the limiting survival factor(s) will drop below a
critical threshold due to natural turnover, activating an intrinsic
axon degeneration program.
This model has several attractions. First, the initial latent phase
of Wallerian degeneration [14,15] would reflect the rate of survival
factor turnover before the critical threshold is reached. Second,
altered turnover would explain how low temperature and
proteasome inhibition extend this latent phase [16–18]. Finally,
redistribution of the remaining survival factor(s) in the distal stump
by axonal transport could underlie the progressive nature of
Wallerian degeneration [14,19,20].
No such endogenous survival factor has been identified, but the
Wld
S protective mechanism offers important clues. Wld
S contains
the N-terminal 70 amino acids of multiubiquitination factor
Ube4b fused, in frame, to NAD
+ synthesizing enzyme Nmnat1
[21]. Both regions are required for full Wld
S function in vivo [4,5].
The N-terminal VCP binding region probably targets the essential
Nmnat activity to a specific subcellular location [2,5]. Despite
being predominantly nuclear [6], recent studies indicate a
cytoplasmic and potentially axonal site of action for Wld
S
[2,3,7,8], rekindling interest in its relationship to the earlier model
of a putative endogenous survival factor(s) [14]. Wld
S, an aberrant
protein, cannot be one of these factors, but Nmnat1 [22] and the
other mammalian Nmnat isoforms (Nmnat2 and Nmnat3 [23,24])
are candidates since they all possess the same critical enzyme
activity and can all delay axon degeneration in primary neuronal
culture when expressed exogenously at high levels [1,25,26]. Only
Nmnat3 has so far been shown to confer robust protection to
PLoS Biology | www.plosbiology.org 1 January 2010 | Volume 8 | Issue 1 | e1000300injured axons in vivo when wild-type proteins (except for a tag
used for detection) are overexpressed [2,4,8].
In support of the ‘‘survival factor delivery hypothesis’’ we show
that briefly suppressing protein synthesis in cell bodies of
uninjured primary neuronal cultures induces Wallerian-like
degeneration. The ability of a single protein (Wld
S) to block this
suggests that only one or a few critical factors are directly
involved. We hypothesized that Wld
S substitutes for one or more
mammalian Nmnat isoforms, so we compared their properties
against those predicted for a critical axon survival factor. We
reasoned that depletion should trigger Wallerian-like degenera-
tion without injury, its natural half-life should be consistent with
the latent phase of Wallerian degeneration (Wld
S should be much
more stable to extend this period), the survival factor should be
degraded by the proteasome to explain why proteasome
inhibition extends axonal survival, it should be present in axons,
and it should significantly prolong injured axon survival when
highly overexpressed (to outweigh its short half-life). Nmnat2
uniquely fits this profile, indicating that its depletion after injury is
a trigger for Wallerian degeneration and that ‘‘dying-back’’
pathology is likely to reflect defects in Nmnat2 axonal transport
or synthesis.
Results
Somatic Protein Synthesis Suppression Induces
Wallerian-Like Degeneration
Our main hypothesis predicts that blocking synthesis of one or
more putative axon survival factors should trigger Wallerian-like
degeneration without injury, similar to that induced by blocking
axonal transport [27,28]. To test this we initially inhibited all
protein translation in mouse superior cervical ganglia (SCG)
explant cultures, using two unrelated inhibitors, cycloheximide
(CHX) and emetine, to rule out nonspecific effects. One mg/ml
CHX, which suppresses global protein synthesis by more than
95% [29,30], not only stopped neurite outgrowth as expected
[30,31] but also induced widespread blebbing of distal neurites
(Figure 1A and 1C). Ten mg/ml CHX or 10 mM emetine caused
more rapid and extensive blebbing of neurites, presumably due to
more complete suppression of protein synthesis, followed by
fragmentation and detachment shortly afterwards (Figure 1A and
1C), similar to the degeneration of transected neurites. To test
whether the degeneration is Wallerian-like, we used cultures from
slow Wallerian degeneration (Wld
S) mice and found a delay of
over 48 h (Figure 1B and 1C). Similar results with rat SCG
cultures and mouse dorsal root ganglion (DRG) cultures indicate
that these events are not restricted to one species or neuron type
(Figure S1). Delayed degeneration in Wld
S cultures after
inhibition of translation also shows that local translation of
mRNAs in neurites is unlikely to underlie Wld
S-mediated axon
protection as hypothesized previously [32]. Similarly, localized
translation is not required in injured neurites for Wld
S-mediated
protection, and it is also not needed for Wallerian degeneration
itself (Figure S2).
Rapid cleavage of neurofilament heavy chain (NF-H) is an early
molecular change that occurs as injury-induced Wallerian
degeneration is initiated after the latent phase both in vitro and
in vivo [6,18]. We found that this also occurs after protein
synthesis suppression in wild-type cultures but not in Wld
S cultures
(Figure 1D). Thus, molecular assays also indicate this degeneration
is Wallerian-like.
Importantly, degeneration induced by protein synthesis
suppression is not due to loss of neuronal viability but is a
much earlier event independent of cell death. Even 7 d after
treatment with 1 mg/ml CHX, long after complete degeneration
of neurites, many SCG cell bodies retain the ability to re-grow
neurites when this reversible inhibitor is removed (Figure 1E).
Most cell bodies in 7-d CHX-treated dissociated cultures also
excluded Trypan Blue, further indicating neuron viability
(unpublished data).
To test directly whether a critical axon survival factor(s) has to
be synthesized and delivered from cell bodies, we used
compartmented cultures where distal neurites can be treated
separately from cell bodies and proximal neurites (Figure 2).
Neurites degenerated only when inhibitors were applied to the
compartment containing neuronal cell bodies and proximal
neurites. Consistent with a previous report [33], translation
inhibitors applied only to distal neurites caused no significant
degeneration within this timeframe. Indeed, neurites continued to
grow (unpublished data). Thus, suppression of protein synthesis in
the cell body triggers Wallerian-like neurite degeneration,
providing strong support for the survival factor delivery hypothesis
and suggesting the survival factor(s) is proteinaceous.
Nmnat2 Knock-Down Induces Wallerian-Like
Degeneration
We then investigated the molecular basis of these findings.
Because Nmnat1 contributes essential Nmnat enzyme activity to
the Wld
S fusion protein, we reasoned that Wld
S might protect
axons by substituting for injury-induced loss of an endogenous
Nmnat activity. Transcripts of all three mammalian Nmnat
isoforms are expressed in mouse SCG neurons (Figure S3 and
[26]), suggesting each is a reasonable candidate. Moreover,
although their predominant localizations are nuclear (Nmnat1),
Golgi-associated (Nmnat2) and mitochondrial (Nmnat3) [34], the
recent finding that Wld
S acts at a non-nuclear site despite its
nuclear abundance [3] reminds us that low levels of protein can
act elsewhere, especially if enzyme activity amplifies the effect. We
therefore decided to test whether any of the Nmnat isoforms
possess the predicted properties of an endogenous axon survival
factor in our model.
The first key prediction is that survival factor depletion should
induce Wallerian-like neurite degeneration without injury as levels
drop below a critical threshold. We used pools of siRNAs
(siNmnat1, 2,o r3) to knock down expression of the murine Nmnat
Author Summary
In a normally functioning neuron, the cell body supplies
the axon with materials needed to keep it healthy. This
complex logistical activity breaks down completely after
injury and often becomes compromised in neurodegen-
erative diseases, leading to degeneration of the isolated
axon. Whilst there are probably many important cargoes
delivered from the cell body that isolated axons cannot
exist without indefinitely, proteins that are short-lived will
be depleted first, so loss of these proteins is likely to act as
a trigger for degeneration. Using clues from a mutant
mouse whose axons are protected from such degenera-
tion, we have identified delivery of Nmnat2, a protein with
an important enzyme activity, as a limiting factor in axon
survival. Importantly, Nmnat2 is very labile and its levels
decline rapidly in injured axons before they start to
degenerate. Even uninjured axons degenerate in a similar
way without it. These properties are consistent with loss of
Nmnat2 being a natural stimulus for axon degeneration,
and it might therefore be a suitable target for therapeutic
intervention.
Nmnat2 Is Required for Axon Survival
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assessing their ability to prevent expression of N-terminal FLAG-
tagged Nmnat (FLAG-Nmnat) proteins in transfected HEK 293T
cells and SCG neurons (Figure 3).
To assess the effect of Nmnat isoform knock-down in SCG
neurons, we used a microinjection-based strategy (see Figure S4),
enabling us to consistently introduce similar amounts of siRNA.
Neurons in wild-type dissociated cultures were first injected with
Figure 1. Protein synthesis suppression induces rapid Wallerian-like degeneration of SCG neurites before loss of neuronal viability.
Representative bright-field images of distal neurites from wild-type (BL/6) (A) and Wld
S (B) mouse SCG explant cultures treated with 1 or 10 mg/ml
CHX or 10 mM emetine as indicated. Images of the same field of distal neurites were captured at the times indicated on the left. Neurites in DMSO-
treated wild-type cultures continue to grow and appear morphologically normal (unpublished data). (C) The fold increase in neurite blebs 12 h after
treatment with CHX or emetine in BL/6 cultures and 48 h after treatment in Wld
S cultures, relative to the same neurites at the start of the treatment
(0 h), was quantified from three or more independent experiments combining data from multiple fields (error bars=6S.E.M.). Blebbing is significantly
reduced in Wld
S cultures even at this much later time point (*p,0.05, **p=0.01, t test Wld
S at 48 h versus BL/6 at 12 h). (D) Anti-NF-H and anti-ß-
Tubulin immunoblots of neurite-only extracts from wild-type or Wld
S SCG explant cultures either treated with 10 mM emetine for 8 h, left untreated,
or 8 h after cut. Each lane represents neurites collected from SCG cultures containing three ganglia. (E) Bright-field images of a mouse SCG explant
after 7 d of treatment with 1 mg/ml CHX and 7 d after CHX removal. Images are representative of three independent experiments.
doi:10.1371/journal.pbio.1000300.g001
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of injected neurons and their neurites. Of the three Nmnat siRNA
pools, only injection of siNmnat2 caused a significant reduction in
the percentage of healthy neurites compared to the non-targeting
siRNA pool (siControl) (Figure 4A and 4B). Some of the neurites of
the siNmnat2-injected neurons already appeared abnormal 24 h
after injection, when the entire lengths of the DsRed2-labeled
neurites could first be clearly visualized, and almost all showed
abnormal morphology or had completely degenerated 72 h after
injection. In contrast, injection of siControl,s i Nmnat1, and siNmnat3
all caused relatively little degeneration (Figure 4A and 4B), and
neurites continued to grow (unpublished data). Combined
injection of all three Nmnat siRNA pools did not significantly
accelerate neurite degeneration relative to siNmnat2 alone
(Figure 4C). Thus, Nmnat2 knock-down is sufficient to induce
neurite degeneration, whereas knock-down of the other Nmnat
isoforms has no clear effect on neurite survival. To confirm that
the siNmnat2-induced neurite degeneration is Wallerian-like, we
microinjected Wld
S neurons with siNmnat2 and found degeneration
was completely blocked for at least 72 h (Figure 4A and 4D).
To rule out a contribution from any off-target effect of the four
individual siRNAs within the siNmnat2 pool, we tested whether
they could cause neurite degeneration when injected individually
or in non-overlapping sub-pools (Figure S5). One siRNA alone (J-
059190-11) and two others in combination (J-059190-10 and J-
059190-12) triggered significant neurite degeneration that was
similar to that induced by the complete pool. A clear combina-
torial effect was also seen as J-059190-11 injected at the
concentration it contributes to the siNmnat2 pool caused
significantly less neurite degeneration than the pool itself.
Together, these observations show that siNmnat2-induced neurite
degeneration is due to knock-down of Nmnat2.
The siNmnat2-induced neurite degeneration is distinctive,
characterized by the appearance of multiple neuritic DsRed2-
containing swellings and a distal-to-proximal ‘‘dying-back’’
progression that appears to be independent of neuronal viability
(Figure 4E and 4F). In contrast, the small amount of background
neurite degeneration seen with all the siRNA pools (including
siControl) coincides with cell death and is faster and morpholog-
ically distinct (Figure 4G).
Some loss of neuronal viability occurred in these experiments,
irrespective of the siRNA injected, but a small, additional decrease
in neuronal viability following siNmnat2 knock-down was also
apparent (Figure S6). Even though this reduction in neuronal
viability, relative to siControl, was proportionately much smaller
than the reduction in neurite survival (Figure S6F), we sought to
completely exclude the possibility that cell death might be
responsible for the siNmnat2-associated neurite degeneration. We
were able to almost completely eliminate neuronal cell death in the
siNmnat2 injection experiments in two ways (Figure 5). First, we
reduced expression of the fluorescent marker after finding that
toxicity was causing the (caspase-independent) background cell
death. Second, we found that the small siNmnat2-associated
decrease in neuronal viability could be prevented by the pan-
caspase inhibitor z-VAD-fmk (Figure 5A), indicating that this
death is caspase-dependent. Importantly, the amount of siNmnat2-
induced neurite degeneration was unchanged when cell death was
reduced in these ways (compare Figure 5C and 5D to Figures 4A,
4B, and S6). This clearly shows that neurite degeneration precedes
any associated loss of neuron viability in these experiments. It is
also consistent with Wld
S-mediated protection of neurites
(Figure 4D) being able to reduce siNmnat2-associated neuronal
loss to control levels (Figure S6C), despite the fact that Wld
S
cannot directly prevent neuronal cell death in SCG cultures [35].
In addition, failure of z-VAD-fmk to prevent siNmnat2-induced
neurite degeneration provides further evidence that it is Wallerian-
like as Wallerian degeneration has been shown to be unaffected by
a range of anti-apoptotic interventions [36–38].
Thus, constitutive expression of endogenous Nmnat2 in SCG
neurons is required to prevent spontaneous ‘‘dying-back’’
Wallerian-like neurite degeneration. Importantly, these data also
indicate that endogenous Nmnat1 and Nmnat3 cannot compen-
sate for loss of Nmnat2, despite the ability of these proteins to
protect injured neurites when sufficiently overexpressed [1,25].
Nmnat2 Is the Most Labile Nmnat Isoform
In our model, axon degeneration is initiated when survival
factor levels drop below a critical threshold after synthesis or
delivery is blocked. If Nmnat2 depletion acts as a trigger for
Wallerian degeneration, Nmnat2 half-life should be compatible
with the short latent phase of 4–6 h before transected SCG
neurites degenerate. Wld
S, on the other hand, should be more
stable to directly substitute for loss of endogenous Nmnat2. A
direct comparison of the relative turnover rates of the FLAG-
tagged murine Nmnat isoforms and Wld
S in co-transfected HEK
293T cells (Figure 6A) showed that FLAG-tagged Nmnat2 is
turned over rapidly when protein synthesis is blocked with an in
vitro half-life of less than 4 h. In contrast, there was minimal
turnover of FLAG-tagged Wld
S, Nmnat1, and Nmnat3 up to
72 h. Similar results were also obtained with C-terminal FLAG-
Figure 2. Neurites degenerate when suppression of protein
synthesis is restricted to the cell body. (A) Diagram showing the
organization of compartmented wild-type mouse SCG cultures. (B)
Representative bright-field images of distal neurites from the side
chamber of a compartmented culture in which 10 mM emetine was
added to either the central chamber (cell bodies treated) or side
chamber (neurites treated). Images of the same field of neurites were
captured just after emetine addition (0 h) and 24 h later. The fold
increase in blebbing at 24 h relative to 0 h (of the same neurites) was
quantified from three independent experiments combining data from
multiple fields (error bars=6S.E.M.) and is shown on the right.
Treatment of cell bodies (CB) alone induces significantly more blebbing
of distal neurites than treatment of the distal neurites (N) themselves
(*p=0.026, t test). Comparable results were obtained with 1 mg/ml CHX
(unpublished data).
doi:10.1371/journal.pbio.1000300.g002
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inhibition with MG-132 largely prevented turnover of FLAG-
tagged Nmnat2 in these cells for at least 24 h (Figure 6B).
Importantly, turnover of endogenous Nmnat2 in SCG explants
following protein synthesis inhibition was found to be similarly
rapid (Figure 6C).
The half-life of Nmnat2 is also consistent with the time when
wild-type SCG neurites become committed to degenerate after
inhibition of translation (Figure S7A). Neurites exposed to CHX
f o rj u s t4hr e m a i nh e a l t h ya n dc o n t i n u et og r o wf o ro v e r5d ,
but they become irreversibly committed to degenerate when
exposed to CHX for just 8 h, despite only minimal evidence of
degeneration when CHX is removed. Intermediate treatment
for 6 h gave a mixed outcome. This suggests that degeneration
of these neurites can be prevented by reestablishing synthesis of
t h el a b i l es u r v i v a lf a c t o r ( s )p r oviding levels have not dropped
below a critical threshold. The precise threshold can only be
determined when the duration of downstream events leading to
activation and execution of degeneration are better understood.
Importantly, Wld
S expression not only delays the onset of
neurite degeneration following protein synthesis suppression, it
also delays their commitment to degenerate at least 3-fold
(Figure S7B).
Therefore, the half-life of Nmnat2, but not Nmnat1 and
Nmnat3, is compatible with its turnover being a trigger for
Wallerian degeneration. Furthermore, the longer half-life of
Figure 3. The Nmnat siRNA pools are specific for their intended targets. (A) Each Nmnat siRNA pool specifically blocks expression of a FLAG-
tagged version of its intended target in transfected HEK 293T cells. Representative FLAG immunoblot of cells 24 h after co-transfection with
expression vectors for each FLAG-Nmnat isoform together with a non-targeting pool of siRNA (siControl) or one of the siNmnat siRNA pools as
indicated. Quantification of band intensities relative to bands in the siControl lane in three independent experiments is shown on the right (error
bars=6S.E.M.). Each siRNA pool specifically and significantly reduces expression of its target (***p,0.001, t test of respective siNmnat versus
siControl). Each FLAG-Nmnat acts as internal control of transfection efficiency for the others. Only 3/4 of the pooled Nmnat2 siRNAs and 2/4 of the
pooled Nmnat3 siRNAs target sequences in the respective expression vectors (compared to 4/4 for the Nmnat1 siRNA pool). All should target the
endogenous mRNAs. (B) Each Nmnat siRNA pool specifically blocks expression of a FLAG-tagged version of its intended target in injected SCG
neurons. Representative fluorescent images of SCG neurons 48 h after co-injection with one FLAG-Nmnat expression vector, pEGFP-C1, and the
relevant siNmnat pool or non-targeting siRNA pool (siControl). eGFP fluorescence identifies injected neurons, FLAG immunostaining shows expression
levels of each FLAG-Nmnat, and DAPI labels nuclei. Each siNmnat siRNA pool significantly reduces expression of its target isoform compared to
siControl as indicated on the right by quantification of FLAG immunostaining relative to eGFP fluorescence in individual neurons (**p,0.01,
***p,0.001, t test of respective siNmnat versus siControl). Data are from three independent experiments in which at total of 36–55 injected neurons
were analyzed (error bars=6S.E.M.) Localization of each tagged isoform is consistent with their expected distribution; Nmnat1 in nuclei and Nmnat2
and Nmnat3 in cytoplasmic compartments.
doi:10.1371/journal.pbio.1000300.g003
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PLoS Biology | www.plosbiology.org 5 January 2010 | Volume 8 | Issue 1 | e1000300Figure 4. Nmnat2 siRNA triggers Wallerian-like degeneration of SCG neurites. (A) Representative fluorescent images of the distal ends of
(DsRed2-labeled) neurites of wild-type (BL/6) or Wld
S SCG neurons 24 and 72 h after injection with non-targeting siRNA (siControl) or siRNA targeting
each Nmnat isoform (siNmnat1, 2, or 3), as indicated, together with pDsRed2-N1 (50 ng/ml) (see also Figure S4). (B) Relative survival of (DsRed2-
labeled) neurites of wild-type SCG neurons injected with siControl,s i Nmnat1,s i Nmnat2,o rs i Nmnat3. The number of healthy DsRed2-labeled neurites
remaining at each time point is shown as a percentage of the total number (both healthy and abnormal) 24 h after injection and was quantified from
three independent experiments combining data from multiple fields (error bars=6S.E.M.). Only siNmnat2 causes significant neurite loss (**p,0.01,
***p,0.001, t test siNmnat2 versus siControl at equivalent time points). (C) Co-injection of siNmnat1, 2, and 3 (each at 100 ng/ml) does not accelerate
Nmnat2 Is Required for Axon Survival
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S is consistent with it substituting for Nmnat2 loss for a
prolonged period.
Endogenous Nmnat2 Degrades Rapidly and
Spontaneously in Injured Neurites
According to our model, the putative axon survival factor
should also be present in neurites under normal conditions, and its
level in transected neurites should drop significantly prior to
initiation of degeneration at 4–6 h. Therefore, we assessed
Nmnat2 levels in neurite-only extracts from SCG explant cultures
at the time of transection and 4 h afterwards when the gross
morphology of the transected neurites still appears relatively
normal (Figure 7A). Neurite extracts contained significant amounts
of Nmnat2 at the time of transection and this fell to ,30% of
steady-state levels within 4 h. Furthermore, loss of endogenous
Nmnat2 occurs before cleavage of NF-H, which accompanies
physical break-down of SCG neurites after injury [18] or protein
synthesis suppression (Figure 1D), and before b-Tubulin degrada-
tion. An increase in Nmnat2 levels in the corresponding cell body/
proximal neurite extracts 4 h after separation of their transected
distal neurites is also seen. This probably represents accumulation
of Nmnat2 in a greatly reduced cellular volume (see Discussion).
Proteasome inhibition modestly extends the latent phase of
Wallerian degeneration in SCG explant cultures [18], so we tested
whether this correlates with reduced turnover of endogenous
Nmnat2 given that FLAG-tagged Nmnat2 is degraded via the
proteasome in HEK cells (Figure 6B). Neurites treated with the
proteasome inhibitor MG-132 appear relatively normal 8 h after
transection, with no associated NF-H cleavage, whereas untreated
neurites show extensive physical and molecular signs of degener-
ation (Figure 7B). We found that loss of Nmnat2 was also
significantly reduced by MG-132 at this time (Figure 7B),
consistent with depletion of endogenous Nmnat2 being a critical
trigger for axon degeneration. The fact that Nmnat2 turnover was
not completely prevented might explain why the duration of
neurite protection by MG-132 is fairly limited [18], although
prolonged proteasome inhibition is also toxic to axons [39].
Nmnat2 loss within 4 h in transected wild-type neurites seems
unlikely to be a consequence of axon degeneration, as cytoskeletal
proteins and neurite morphology are little altered at this time point
(Figure 7A). However, to rule this out conclusively, we assessed
Nmnat2 turnover in transected Wld
S neurites (Figure 7C), which
do not degenerate for several days. Nmnat2 levels in Wld
S neurites
fell with a remarkably similar time course to those in wild-type
neurites. In contrast, cleavage of NF-H was prevented, showing
that proteins that degrade as a consequence of degeneration are
stabilized in Wld
S neurites. As predicted, Wld
S levels in neurites
also remained relatively constant. Indeed, levels of Wld
S protein
are only moderately reduced in neurites 48 h after transection
(Figure S8).
Thus, Nmnat2 is rapidly depleted in distal stumps of injured
neurites, as a result of natural turnover rather than a consequence
of degeneration. This is consistent with Nmnat2 loss triggering
Wallerian degeneration. The continued presence of Wld
S in
transected Wld
S neurites long after Nmnat2 is lost shows that Wld
S
does not act by stabilizing Nmnat2 but instead supports a model in
which Wld
S substitutes for the functionally related Nmnat2.
Net Anterograde Delivery of Nmnat2 by Fast Axonal
Transport
We also found that an Nmnat2–enhanced green fluorescent
protein (eGFP) fusion protein localizes to SCG neurites in highly
defined particles shortly after being expressed (Video S1 and
Figure 7D). In contrast, eGFP alone showed uniform distribution
in neurites (unpublished data). Particles containing Nmnat2-eGFP
travel bi-directionally, but the majority move in an anterograde
direction (72.2%63.8% based on particle movements in 18
neurites). The average and maximal velocities of particles moving
anterogradely (0.5860.09 and 1.5260.12 mm/sec) and retro-
gradely (0.2960.06 and 1.1860.10 mm/sec) are consistent with
fast axonal transport. This indicates that Nmnat2 undergoes rapid
net anterograde delivery from the cell body to neurites. This is
another important prediction of our model, as rapid delivery is
needed to replenish constant turnover of Nmnat2 in distal neurites
(above).
Nmnat2 Protects Transected Neurites When Highly
Overexpressed
Finally, if Nmnat2 is an endogenous axon survival factor,
overexpression should protect transected neurites by preloading
them with increased amounts of the protein. However, due to its
relatively short half-life, protection should be highly dose-
dependent and prolonged protection might only be achieved with
very high levels of Nmnat2. In contrast, relatively long-lived Wld
S
should also confer protection at much lower levels.
We tested the ability of exogenous expression of tagged Nmnat2
and Wld
S to protect transected neurites in a microinjection-based
assay (Figure S9). Dilution of the injected construct allowed
controlled amounts to be reproducibly introduced into neurons. At
low vector concentration (1 ng/ml), Wld
S conferred robust
protection to neurites for 24 h after cutting, whereas Nmnat2
provided almost no protection (Figure 8A and 8B). In contrast, at
50-fold higher construct concentrations, both Nmnat2 and Wld
S
conferred protection to almost all cut neurites at 24 h (Figure 8A
and 8B). Although we used identical expression cassettes to give
the best chance of equal expression of the two proteins in this
assay, the shorter half-life of FLAG-Nmnat2 probably manifests as
a lower steady-state level at the time of cut relative to FLAG-Wld
S.
Indeed, in transfected HEK 293T cells, we found that 2.5 times
more FLAG-Nmnat2 construct was required to give steady-state
protein levels approximately equal to FLAG-Wld
S (and the other
Nmnat isoforms). Importantly, whilst we found that injection of
the FLAG-Nmnat2 construct at 2.5 ng/ml gave slightly increased
protection 24 h after cut relative to 1 ng/ml, this was still greatly
reduced protection compared to the FLAG-Wld
S construct at the
lower concentration (Figure 8A). Thus exogenous Nmnat2 only
confers significant protection of cut neurites when expressed at
(wild-type) neurite loss compared to injection of siNmnat2 alone (100 ng/ml). Data were quantified as in (B) from three independent experiments
(error bars=6S.E.M.). (D) Neurite loss caused by siNmnat2 injection is abolished in Wld
S SCG neurons up to 72 h after injection (**p,0.01,
***p,0.001, t test Wld
S versus BL/6 at equivalent time points). Data were quantified as in (B) from four independent experiments (error
bars=6S.E.M.). (E–G) Representative fluorescent images showing the typical characteristics of the neurite degeneration caused by siNmnat2
injection. Multiple DsRed2-positive neuritic swellings are only observed after siNmnat2 injection (E) and these precede a characteristic progressive
distal-to-proximal ‘‘dying-back’’ neurite degeneration (F). Neurites showing ‘‘dying-back’’ degeneration can be followed back to morphologically
normal cell bodies. This contrasts the more rapid, catastrophic neurite degeneration that coincides with cell body death (G) and is seen following
injection of all siRNA pools (including siControl). Images in (E) were captured 48 h after injection and show injected cell bodies at the top of each
panel.
doi:10.1371/journal.pbio.1000300.g004
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PLoS Biology | www.plosbiology.org 7 January 2010 | Volume 8 | Issue 1 | e1000300Figure 5. Neurite degeneration following siNmnat2 injection precedes loss of neuronal viability. (A) Viability of wild-type SCG neurons
injected with non-targeting siRNA (siControl)o rNmnat2 siRNA (siNmnat2), together with pEGFP-C1 (10 ng/ml), and treated with 50 mM z-VAD-fmk or
vehicle (DMSO) as indicated. The number of neurons with normal gross morphology remaining at each time point is shown as a percentage of those
present at 24 h and was quantified from three independent experiments (error bars=6S.E.M.). There is a small but significant decrease in the
percentage of viable neurons 48 and 72 h after injection with siNmnat2 (+DMSO) relative to siControl (***p,0.001, t test siNmnat2 versus siControl at
equivalent time points), but this is reduced to control levels following treatment with z-VAD-fmk. (B) Assessment of neuronal viability based on gross
morphology matches that based on other indicators of viability. At the end of experiments in (A), neurons were counter-stained with propidium
iodide (PI), a DNA stain that can only penetrate the membranes of non-viable cells, and DAPI. Abnormal gross morphology seen with bright-field and
eGFP imaging correlated precisely with PI staining and nuclear condensation/fragmentation (revealed by DAPI staining) typical of cell death. An
arrowhead indicates an abnormal neuron (rarely seen in these experiments) and an arrow a healthy neuron. (C) Quantification of neurite survival
corresponding to the analysis of neuronal viability in (A). The number of healthy eGFP-labelled neurites remaining at each time point (quantified from
multiple fields in each experiment) is shown as a percentage of the total number (both healthy and abnormal) 24 h after injection (error
bars=6S.E.M.). Significant neurite loss is seen following siNmnat2 injection irrespective of treatment with z-VAD-fmk (*p,0.05, **p,0.01,
***p,0.001, t test siNmnat2 6 z-VAD-fmk versus siControl 6 z-VAD-fmk at equivalent time points) with no significant difference between the two. (D)
Representative fluorescent images of the distal ends of eGFP-labelled neurites of wild-type (BL/6) SCG neurons 24 and 72 h after injection with
siControl or siNmnat2 and treated with z-VAD-fmk.
doi:10.1371/journal.pbio.1000300.g005
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Wld
S protects even at low levels.
Discussion
Our results provide direct support for the hypothesis that
constant delivery of a labile, cell body–synthesized survival factor
is required to stop healthy mammalian axons undergoing
Wallerian degeneration. Defects that prevent its delivery, includ-
ing axon injury [6,40], axonal transport impairment [27,41], cell
death [35], or disruption of protein synthesis in the cell body
(Figures 1 and 2), all trigger Wld
S-sensitive axon degeneration. We
identify Nmnat2 as one such critical axon survival factor, required
to maintain normal axon integrity and sufficient to preserve
injured ones at high doses. Nmnat2 half-life, uniquely among the
three Nmnat isoforms, is consistent with the timing of the latent
phase of Wallerian degeneration and commitment to degenerate
in primary culture. We also show for the first time that endogenous
Nmnat2 is present in neurites, where levels drop rapidly after
injury. Importantly, this is not a consequence of neurite
degeneration but represents natural turnover prior to activation
of degeneration. These findings have significant implications for
our molecular understanding of Wallerian degeneration and
‘‘dying-back’’ axonopathies, and for the mechanism by which
Wld
S and other Nmnat isoforms delay axon degeneration.
The most compelling evidence that Nmnat2 is required for
maintenance of healthy axons is our observation that siRNA-
mediated knock-down of Nmnat2 alone induces neurite degener-
ation in the absence of injury and that this precedes any effect
on neuronal viability. The initiation and progression of this
degeneration is clearly slower than that caused by protein synthesis
suppression, but this is consistent with the mechanisms involved.
The critical rate-limiting factor following translation inhibition is
protein half-life, but for siRNA-mediated knock-down additional
time is needed for mRNA degradation. Pharmacological inhibi-
tion of translation could also result in more efficient and
homogenous knock-down. It is also possible that depletion of
other axon survival factors after global suppression of protein
Figure 6. Nmnat2 is the most labile Nmnat isoform and is degraded by the proteasome. (A) Relative stabilities of FLAG-tagged Nmnat
isoforms and Wld
S in HEK 293T cells co-transfected with expression vectors for each and treated 24 h after transfection with 10 mM emetine to block
translation for the times indicated. A representative FLAG immunoblot is shown (top panel). The same blot was re-probed with an Nmnat2 antibody
(bottom panel) to show that loss of anti-FLAG signal is primarily due to protein turnover rather than cleavage of the FLAG epitope from the protein.
Quantification of band intensities for each protein from three independent experiments is shown below as a percentage of untreated (0 h) band
intensities (error bars=6S.E.M.). Co-transfection allows direct comparison of stabilities of each protein in the same cells. (B) FLAG-Nmnat2 turnover in
transfected HEK 293T cells is prevented by proteasome inhibition. Cells were transfected as in (A) and treated with 10 mM emetine for 0 or 24 h,
620 mM MG-132. A FLAG immunoblot representative of three independent experiments is shown. (C) Endogenous Nmnat2 is rapidly turned over in
SCG explant cultures after blocking translation with CHX (1 mg/ml) or emetine (10 mM). Representative immunoblots are shown comparing steady-
state levels of Nmnat2 (0 h) with levels after 4 h of protein synthesis suppression. ß-Tubulin acts as a loading control. Nmnat2 band intensity at 4 h is
shown as a fraction of that at 0 h after normalization to ß-Tubulin and was quantified from two independent experiments each (error bars=6S.E.M.).
These values are consistent with the different rates at which CHX (1 mg/ml) and emetine induce neurite degeneration (Figure 1).
doi:10.1371/journal.pbio.1000300.g006
Nmnat2 Is Required for Axon Survival
PLoS Biology | www.plosbiology.org 9 January 2010 | Volume 8 | Issue 1 | e1000300Figure 7. Endogenous Nmnat2 is present in SCG neurites and undergoes rapid turnover after transection. (A–C) Relationship between
Nmnat2 turnover in neurites and other parameters of neurite health in wild-type cultures (A), wild-type cultures 620 mM MG-132 (B), and Wld
S
cultures (C). Representative immunoblots show detection of Nmnat2, Wld
S (where applicable), NF-H, 16 kDa core Histones, and ß-Tubulin just after
cut (0 h) and 4 and/or 8 h later. Material collected from SCG explant cultures derived from 15–20 ganglia was needed to detect Nmnat2 in each lane.
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Nmnat3 seem unlikely to be among them in this experimental
system because of their long half-lives, the absence of any clear
effect of their siRNAs, and the fact that endogenous levels of both
proteins cannot compensate for loss of Nmnat2.
Nmnat2 is a labile protein in HEK cells, in whole SCG
explants, and in transected neurites. The rate of Nmnat2 turnover
is consistent with the trigger for axon degeneration being depletion
below a critical threshold. Nmnat2 falls to barely detectable levels
in transected wild-type SCG neurites prior to any significant
physical signs of degeneration, which suggests that the critical
threshold level of Nmnat2 is quite low. However, the precise
threshold level is difficult to determine because the duration of
downstream steps needed to bring about degeneration is unknown.
Steady-state levels of Nmnat2 in SCG neurites also seem quite low
and this could account for the short latent phase between neurite
transection and degeneration in these cultures.
Of the three mammalian Nmnat isoforms, Nmnat2 did not
initially appear the most obvious candidate for an endogenous
axon survival factor, despite being the most abundantly expressed
isoform in the nervous system at the mRNA level [23,34]. First, its
predominant Golgi localization seemed inconsistent with an
axonal location. However, a recent report shows axons in primary
neuronal cultures contain Golgi components [42] and, as with
Wld
S [3], predominant localization may not reflect the site of its
axon protective role. We have now clearly detected endogenous
Nmnat2 in SCG neurites by immunoblotting and have shown that
an Nmnat2-eGFP fusion localizes to distinct, rapidly transported
particles in these neurites (Figure 7 and Video S1). It will be
interesting to determine the precise nature of these particles.
Second, the inability of Nmnat2 to protect 5-d lesioned axons in
Drosophila, unlike the other Nmnat isoforms and Wld
S, initially
suggested it was either ineffective or by far the least potent isoform
[2]. However, it has more recently been shown that exogenous
expression of Nmnat2 can protect injured mammalian axons [26].
We propose that the short half-life of Nmnat2 could provide an
explanation for this discrepancy, with the degree of protection
being related to the levels of Nmnat2 expression achieved in the
different systems. It is also possible that some protection of lesioned
Drosophila axons might be evident at a less stringent time point
(wild-type fly axons begin to degenerate just 1 d after injury).
Thus, a short half-life, one of the most critical inherent properties
of the endogenous survival factor in our model, might mask the
capacity of exogenous Nmnat2 to protect in some situations.
Conversely, greater stability probably underlies the ability of
exogenous Nmnat1 and Nmnat3 to protect injured axons/neurites
more robustly in this and other in vivo and/or in vitro situations
[1,2,8,25].
Our data suggest that Wld
S may protect axons by directly
substituting for loss of endogenous Nmnat2 after injury or other
stresses. This is based on three principal observations. First, Wld
S
is inherently more stable than Nmnat2, decaying less in 48 h than
Nmnat2 does in 4 h after neurite transection (Figures 6, 7, and S8).
Importantly, continued degradation of Nmnat2 in Wld
S neurites
rules out an alternative hypothesis, that Wld
S could delay axon
degeneration by stabilizing Nmnat2. Second, Wld
S and Nmnat2
share the same enzyme activity, which is required for their ability
to protect axons [5,26,43]. Third, both are present in axons
(Figure 7, Video S1, and [3]), and the presence of Wld
S in
microsome fractions [3,8] is consistent with a possible shared
localization with Nmnat2 in Golgi, or Golgi-derived structures in
axons [42].
The ability of exogenous nuclear Nmnat1 and mitochondrial
Nmnat3 to confer axon protection in a number of situations
outwardly seems to contradict the claim that Nmnat localization is
actually important, but there is increasing evidence to support it.
First, endogenous Nmnat1 and Nmnat3 (which do appear to be
expressed in SCG neurons; Figure S3) cannot compensate for loss
of Nmnat2 (Figure 4), probably as a result of strict compartmen-
talization. Alternatively, this could simply reflect the relative
contributions of each isoform to total basal Nmnat activity in these
axons. Second, redistribution of predominantly nuclear Wld
S and
Nmnat1 into the cell body and axon enhances their ability to delay
Wallerian degeneration [3,7,8]. Finally, Nmnat1 and Nmnat3
only confer protection when overexpressed. This appears to be
accompanied by significant mis-localization (Figure 3B, unpub-
lished observations, and [8]), which may cause a serendipitous
increase in effective Nmnat levels in the relevant axonal location.
The ability of barely detectable extra-nuclear Wld
S to protect
injured Wld
S mouse axons suggests that minimal mis-localization
of relatively stable Nmnat1 and Nmnat3 may be sufficient to
confer strong protection. The absence of significant axon
protection in transgenic mice expressing Nmnat1 in neurons at
similar levels to Wld
S in Wld
S neurons [4,8] suggests either that
Nmnat1 localization is more rigorously controlled in vivo or that
Nmnat1 overexpression is greater in vitro. Importantly, Nmnat1
can only protect mammalian axons in vivo when specifically
mutated to cause mis-localization [7].
The main known function of the mammalian Nmnat isoforms is
NAD
+ biosynthesis, and the ability of Nmnat1, Nmnat2, and Wld
S
to delay Wallerian degeneration requires Nmnat enzyme activity
[1,5,26,43]. NAD
+ production may therefore underlie the ability
of endogenous Nmnat2 to prevent spontaneous axon degenera-
tion. However, there is much disagreement over the ability of
NAD
+ to protect axons directly [1,4,8,44,45], or even its
involvement at all [43]. Indeed, siRNA-mediated knock-down of
Nampt, the rate-limiting enzyme upstream of Nmnat in the NAD
+
salvage pathway, does not itself trigger axon degeneration despite
a substantial 70%–90% reduction in NAD
+ levels, leading to the
suggestion that an alternative Nmnat metabolite may be involved
[43].
Regarding downstream events, the rapid initiation and
progression of Wallerian degeneration is more consistent with an
active degeneration program than passive degeneration resulting
simply from loss of an essential metabolic activity. Recently, dual
leucine kinase (DLK) and JNK signalling have been implicated in
Loss of the NF-H band is an early consequence of axon degeneration and absence of the 16 kDa core Histones band in neurite extracts confirms there
is no detectable contamination with SCG cell bodies or non-neuronal cells. ß-Tubulin represents a loading control. Relative Nmnat2 band intensities
in neurite-only lanes are shown as a fraction of levels at 0 h after normalisation to ß-Tubulin and were quantified from two or three independent
experiments (error bars=6S.E.M.). Nmnat2 is significantly depleted in untreated wild-type and Wld
S neurites shortly after separation from their
ganglia (*p,0.05, **p,0.01, ***p,0.001, t test 4 or 8 h versus 0 h). Proteasome inhibition with MG-132 significantly reduces this Nmnat2 loss at 8 h
after transection (
11p,0.01, t test 8 h +MG-132 versus 8 h untreated). Images show representative transected neurite morphology (in the same field
where applicable) at the indicated times after cut. (D) Kymograph of the bottom axon in Video S1 showing fast axonal transport of particles
containing Nmnat2-eGFP with a bias in the anterograde direction. An image series from the indicated region of the kymograph is shown on the right.
It highlights a particle moving anterogradely (filled arrowhead), one moving retrogradely (empty arrowhead), and several stationary particles
(asterisks).
doi:10.1371/journal.pbio.1000300.g007
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PLoS Biology | www.plosbiology.org 11 January 2010 | Volume 8 | Issue 1 | e1000300Figure 8. Exogenous Nmnat2 protects transected neurites for prolonged periods only when highly overexpressed. (A) Protection of
transected neurites by exogenous expression of FLAG-Nmnat2 or FLAG-Wld
S (see also Figure S9). SCG neurons injected with 1, 2.5, or 50 ng/ml empty
vector (FLAG-empty) or FLAG-Nmnat2 or FLAG-Wld
S expression vectors, together with pDsRed2-N1 (50 ng/ml), were transected 48 h later. Survival of
DsRed2-labeled neurites 24 h after transection is shown as a percentage of the number of labelled neurites with normal morphology just after cut
(0 h) and was quantified from two to four independent experiments combining data from multiple fields (error bars=6S.E.M). FLAG-Wld
S protects
neurites significantly better than FLAG-Nmnat2 24 h after cut at the 1 ng/ml vector concentration (***p,0.001, t test). There is no significant
difference in protection 24 h after transection at the 50 ng/ml vector concentration. (B) Representative fluorescent images of transected DsRed2-
labeled neurites of SCG neurons injected with selected concentrations of FLAG-Nmnat2 or FLAG-Wld
S expression vectors (as indicated). The same
field of neurites is shown at the time of cut (0 h) and 24 h later. The cut site is located to the left of each image. Increased magnification of the framed
region in each panel is shown for better visualization of neurite morphology.
doi:10.1371/journal.pbio.1000300.g008
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found the same JNK inhibitor (SP600125) used in that study also
significantly delays Wallerian degeneration of SCG neurites
(unpublished data). The localization of Nmnat2 in defined
particles in axons and the role it plays in them could now be
key to identifying additional downstream events.
Whilst neurite degeneration in primary neuronal cultures is a
useful model of in vivo axon degeneration, high levels of protein
overexpression can give misleading outcomes (discussed above)
and other differences need to be considered. For example, there is
a much longer latent phase before fragmentation of axons in
transected sciatic nerves in vivo (36–40 h [15]) than for transected
SCG neurites in culture (,8 h). This could reflect differences in
the half-life of Nmnat2 in vivo and in culture (for which there is
some precedent [47]), steady-state levels of Nmnat2, or the
involvement of additional factors that are more critical for axon
survival in vivo. However, it would be somewhat surprising if
Nmnat2 did not play a critical role in vivo based on its rapid
turnover and it being required for neurite survival in vitro. Other
Nmnat isoforms remain candidates in vivo, particularly Nmnat3 as
its mitochondrial localization makes its presence in axons likely.
Indeed, a contribution from other molecules could help to explain
the longer latent phase in vivo.
It will also be interesting to see whether endogenous Nmnat
proteins are involved in axon survival in non-mammalian
organisms such as Drosophila. Whilst loss of the single Drosophila
Nmnat homolog causes degeneration of photoreceptors, this
appears to be a more general effect on neuronal viability, rather
than axon health, and does not require its NAD
+-synthesizing
activity [48]. This contrasts with the protection against axon
degeneration by mammalian Nmnat isoforms and Wld
S, which
does require enzyme activity [1,5,26,43]. Neuronal viability could
therefore be dependent on a reported Nmnat-associated chaper-
one activity [49], with axons having a more specific dependency
on enzyme activity. Thus, it is possible that the small decrease in
neuron survival associated with Nmnat2 knock-down in SCG
neurons (Figure 5A) could be due to loss of chaperone activity,
although it is not yet known whether Nmnat2 possesses this
activity like the other mammalian isoforms [49].
Loss of Nmnat2 could also underlie ‘‘dying-back’’ axon
degeneration in disease. Due to its rapid turnover, Nmnat2 might
fail to reach distal axons in sufficient quantities when axonal
transport is either pathologically compromised [12,27,50] or slows
during normal ageing [51]. Impairment of protein synthesis would
be predicted to have a similar outcome, which could explain axon
degeneration accompanying viral infections as the cellular protein
synthesis machinery is overwhelmed [52]. More subtle effects on
protein synthesis resulting from cell body defects, such as
vacuolization, could underlie Wallerian-like ‘‘dying-back’’ axon
degeneration and/or neuromuscular junction loss in slowly
developing, chronic diseases like ALS [53,54], even in the absence
of neuronal loss. Our model would additionally explain why the
longest axons are often most susceptible in disease. The ability of
some larger mammals to support very long axons (up to several
meters in some cases) raises the intriguing possibilities that
Nmnat2 is inherently more stable in larger species or that
chaperones stabilize it during transport.
We propose that increasing Nmnat2 stability or its delivery to
axons could have important therapeutic implications for these and
other disorders characterized by Wallerian-like degeneration. Both
treatments should delay the point at which axons become
committed to degenerate (like Wld
S). Such therapies might be
particularly effective when axonopathy results from a short-term
impairment (e.g., of cell body metabolism, axonal transport, glial
support, etc.) lasting just a few hours to a few weeks. Examples
include Taxol-induced neuropathy, relapsing-remitting multiple
sclerosis, some viral disorders, and stroke. Axons could be saved
permanently if the degeneration commitment point is delayed long
enough for the causative defect to be removed or to abate
naturally. Although Wld
S mice have already been shown to be
resistant to Taxol-induced neuropathy [41], developing therapies
based on the Wld
S neuroprotective mechanism has been limited
by the technical challenge of introducing exogenous Wld
S (or
other stable Nmnat isoforms). In contrast, pharmacological
manipulation of endogenous Nmnat2 should be more feasible.
Finally, the increase in Nmnat2 levels in SCG cell bodies/
proximal neurite stumps that we observed shortly after transection
of their neurites is also intriguing (Figure 7A). The simplest
explanation is that this represents accumulation of Nmnat2 in a
reduced cellular volume following neurite removal while synthesis
continues at pre-injury levels. However, the possibility that this
could represent a stress response cannot be completely excluded at
this time, especially in light of the recent report that the Drosophila
Nmnat isoform can act as a chaperone [49]. Irrespective of the
mechanism involved, this increase in Nmnat2 levels might
nevertheless facilitate subsequent neurite regeneration.
In summary, we propose a model in which sustained expression
and anterograde delivery of Nmnat2 is required to prevent
activation of an intrinsic axon degeneration program. Degener-
ation is triggered when synthesis and/or delivery of Nmnat2 is
disrupted and rapid turnover causes its level to drop below a
critical threshold. We additionally propose that the relatively stable
Wld
S fusion protein delays axon degeneration by directly
substituting for loss of Nmnat2 and that localization may be an
important factor. Endogenous Nmnat2 represents an exciting
target for therapeutic manipulation.
Materials and Methods
Plasmids Constructs and siRNA Reagents
Expression vectors encoding FLAG-tagged murine Nmnat
isoforms and Wld
S were generated by amplification of the full
coding region of each gene by Reverse Transcriptase PCR (RT-
PCR) (see below) from 1 mg total RNA from wild-type and Wld
S
mouse brain. Products were cloned into pCMV Tag-2B
(Stratagene) to generate FLAG-Nmnat/Wld
S expression vectors
or pEGFP-N1 (BD Biosciences Clontech) to generate a Nmnat2-
eGFP expression vector. Sequencing (Cogenics) was performed to
confirm the absence of PCR errors. Other plasmids used were
pDsRed2-N1 for expression of variant Discosoma red fluorescent
protein (DsRed2) and pEGFP-C1 for expression of eGFP (both
BD Biosciences Clontech). Dharmacon ON-TARGETplus
SMART pools of siRNA (Thermo Scientific) specifically targeted
against mouse Nmnat1 (L-051136-01), Nmnat2 (L-059190-01), or
Nmnat3 (L-051688-01) were used in this study. Dharmacon ON-
TARGETplus siControl non-targeting siRNA pool (D-001810-10)
was used as a control in experiments. Each pool consists of 4
individual siRNAs. The siRNAs making up the ON-TARGETplus
Nmnat2 SMART pool (J-059190-09, -10, -11, and -12) were also
tested individually or in subpools.
Cell Culture
Explant cultures. SCGs were dissected from P1 or P2 mouse
or rat pups, and DRGs were dissected from E15.5 mouse embryos.
Cleaned explants were placed in the centre of 3.5 cm tissue culture
dishes pre-coated with poly-L-lysine (20 mg/ml for 1–2 h; Sigma)
and laminin (20 mg/ml for 1–2 h; Sigma). Explants were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4,500
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glutamine, 1% penicillin/streptomycin, 100 ng/ml 7S NGF (all
Invitrogen), and 10% fetal bovine serum (Sigma). Four mM
aphidicolin (Calbiochem) was used to reduce proliferation and
viability of small numbers of non-neuronal cells. Cultures were
used after 5–7 d.
Dissociated SCG cultures. Dissected SCG ganglia were
incubated in 0.025% trypsin (Sigma) in PBS (without CaCl2 and
MgCl2) for 30 min followed by 0.2% collagenase type II (Gibco)
in PBS for 30 min. Ganglia were then gently triturated using a
pipette. After a 2-h pre-plating stage to remove non-neuronal
cells, 5–10,000 dissociated neurons were plated in a 1 cm
2
poly-L-lysine and laminin-coated area of normal 3.5 cm dishes
(Nunc) or ibidi m-dishes (Thistle Scientific) for microinjection
experiments. Dissociated cultures were maintained as explant
cultures except that 20 mM uridine and fluorodeoxyuridine was
used to reduce proliferation and viability of non-neuronal cells
(Sigma).
Compartmented cultures. Dissected SCG explants were
broken into small pieces using forceps and then placed into the
central compartment of three-compartment Campenot Teflon
divider (Tyler Research) essentially as described previously [55].
The ability of the barriers to prevent diffusion of bromophenol blue
between the independent compartments containing the cell bodies
and distal neurites for at least 24 h after completion of the
experiment was assessed to confirm their integrity. Compart-
mented cultures were maintained as explant cultures.
HEK 293 culture. HEK 293 cells were cultured under
standard conditions in DMEM with 4,500 mg/L glucose and
110 mg/L sodium pyruvate (PAA), supplemented with 2 mM
glutamine and 1% penicillin/streptomycin (both Invitrogen), and
10% fetal bovine serum (Sigma).
Animals. C57BL/6JOlaHsd and homozygous C57BL/
6OlaHsd-Wld (Wld
S) mice and Sprague Dawley rats were
obtained from Harlan UK (Bicester, UK). Transgenic Wld
S rat
line 79 has been described previously [56]. All animal work was
carried out in accordance with the Animals (Scientific Procedures)
Act, 1986, under Project Licenses PPL 80/1778 and 80/2254.
RT-PCR
Total brain RNA was extracted using TRIzol reagent (Invitro-
gen), and RNA from dissociated SCG neuronal cultures was isolated
using RNeasy columns (Qiagen). One mg of brain RNA and 30% of
that recovered from SCG cultures was reverse transcribed into
cDNA using Superscript II (both Invitrogen). Control samples
without reverse transcriptase were processed simultaneously to rule
out DNA contamination of samples. Standard PCR amplification
was performed using REDTaq DNA polymerase (Sigma). Primers
used for detection of Nmnat isoform transcripts in SCG neuron RNA
were as follows: Nmnat1 59-ttcaaggcctgacaacatcgc-39 and 59-
gagcaccttcacagtctccacc-39, Nmnat2 59-cagtgcgagagacctcatccc-39 and
59-acacatgatgagacggtgccg-39, Nmnat3 59-ggtgtggaggtgtgtgacagc-39
and 59-gccatggccactcggtgatgg-39. Products were sequenced to
confirm correct amplification.
Inhibitor Treatments
1,0006 aqueous stock solutions of emetine (dihydrochloride
hydrate) and CHX in DMSO (both Sigma) were diluted 1:1000 in
culture media to give final concentrations indicated (1 mg/ml
CHX=3.5 mM). InSolution MG-132 (Calbiochem) was diluted to
20 mM. MG-132 was added to SCG explant cultures 3 h prior to
neurite transection. This pre-treatment is required to see neurite
protection in these cultures [18]. Media was changed once with
addition of fresh inhibitors when cultures were treated for more
than 5 d. CHX-containing media was completely removed and
replaced with media containing no CHX in experiments involving
temporary suppression of protein synthesis.
Microinjection and Immunostaining
Microinjection was performed on a Zeiss Axiovert 200
microscope with an Eppendorf 5171 transjector and 5246
micromanipulator system and Eppendorf Femtotips. Plasmids
and siRNAs were diluted in 0.56PBS and passed through a Spin-
X filter (Costar). The mix was injected directly into the nuclei of
SCG neurons in dissociated cultures. ON-TARGETplus siRNA
pools were injected at a concentration of 100 ng/ml and individual
siRNAs or sub-pools as indicated in the text, pDsRed2-N1 at
50 ng/ml, pEGFP-C1 at 10 ng/ml, the Nmnat2-eGFP expression
construct at 50 ng/ml, and FLAG-Nmnat/Wld
S expression
constructs or FLAG-empty control (pCMV Tag-2B) at 10 ng/ml
for siRNA-mediated knock-down analysis by immunostaining
(Figure 3B) and at 1, 2.5 or 50 ng/ml in neurite transection
experiments (Figure 8 and Figure S9). Seventy to 150 neurons
were injected per dish. Injection of relatively few neurons per dish
facilitated visualization of individual labelled neurites as neurites
tend to cluster together in bundles. For detection of FLAG-tagged
protein expression by immunostaining, neurons were fixed with
4% paraformaldehyde (20 min), permeabilized with 1% Triton X-
100 in PBS (10 min), blocked in 50% goat serum in PBS
containing 1% BSA (30 min), and stained using monoclonal M2
anti-FLAG (Sigma) (1:400 in PBS, 1% BSA for 1 h) and an
Alexa568-conjugated secondary antibody (1:200 in PBS, 1% BSA
for 1 h). Cells were mounted in Vectashield containing DAPI
(Vector Laboratories) for counterstaining of nuclei. For comparing
the quantification of neuronal viability based on gross morphology
with other indicators of health (Figure 5B), cultures were incubated
with 1 mg/ml propidium iodide (Invitrogen) for 15 min and were
then fixed with 4% paraformaldehyde (20 min) before being
mounted in Vectashield containing DAPI.
Neurite Transection for Imaging and Quantification of
Degeneration
Neurites were cut with a disposable scalpel roughly half-way
between their cell bodies and their most distal ends. Where
applicable, inhibitors of translation or vehicle (DMSO) were added
to the media less than 10 min before transection. Uncut neurites
treated with DMSO continue to grow normally (unpublished
data). Microinjection of a row of cell bodies in dissociated SCG
cultures enabled neurites to be cut so that all injected cell bodies
and their proximal neurites were located on the opposite side of
the cut site to the distal stumps (Figure S9).
Western Blot Analysis
HEK 293 transfection. Cells were plated so that they
reached 60%–80% confluence on the day of transfection and
were transfected using Lipofectamine 2000 reagent (Invitrogen).
For turnover experiments (Figure 6), cells in a 12-well dish format
were co-transfected with 100 ng each of the FLAG-Nmnat1,
FLAG-Nmnat-3, and FLAG-Wld
S expression constructs and
250 ng of the FLAG-Nmnat-2 expression construct. For
specificity experiments (Figure 3), 1 mg of one of the siRNA
pools was also added as indicated. After the treatments described
in the text, cells were lysed directly into 26Laemmli sample buffer
after washing with PBS.
SCG neurite extract preparation. Following treatment (as
indicated), ganglia in 6- or 7-d-old SCG explant cultures were
separated from their neurites with a scalpel. Ganglia (including
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washed in PBS, and lysed and processed as above.
Immunoblotting. Extracts were separated by standard SDS-
PAGE on SDS polyacrylamide gels (6%–13% depending on the
proteins being detected) and transferred to Immobilon-P
membrane (Millipore) using the Bio-Rad Mini-PROTEAN III
wet transfer system. Blots were blocked and incubated with
primary antibodies overnight (in 16 TBS p.H. 8.3, with 0.05%
Tween 20 and 5% milk powder or 5% BSA) followed by the
appropriate HRP-conjugated secondary antibody (1 h at 1:2000–
1:5000 dilution) and detection by ECL (Amersham Pharmacia
Biotech) with washes between each stage. The following primary
antibodies were used: mouse monoclonal anti-FLAG (1:2000–
1:5000, Sigma, M2), rabbit polyclonal anti-Wld
S (1:4000, Wld18),
mouse monoclonal anti-NF-H (1:2000, Sigma, N52), mouse
monoclonal anti-Nmnat2 (2.0 mg/ml, Abcam, ab56980), mouse
monoclonal anti-neuronal class bIII-Tubulin (1:2000–1:10,000,
Covance, MMS-435P), and mouse monoclonal anti-Histones
(1:1000, Millipore, MAB052). In Figures 6C, 7A, 7B, and 7C,
exactly 10% of the extract that was used for the blot probed with
the Nmnat2 antibody (and Wld
S and Histones antibodies where
applicable) was used for the blot probed with the b-Tubulin
antibody (and NF-H antibody where applicable) to avoid signal
saturation. Relative band intensities on scanned autoradiographs
were determined using ImageJ software version 1.43 (NIH,
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/). Statistical
analysis was performed using a two-tailed t test.
Microscopy and Imaging
Bright-field and fluorescence images were captured on an
Olympus IX81 inverted fluorescence microscope using a Soft
Imaging Systems F-View camera linked to a PC running the
appropriate imaging software. Wherever possible, images of the
same field of neurites or neuronal cell bodies were captured at the
indicated time points after initial manipulation. Images were
processed using Adobe Photoshop Elements 4.0. The intensity of
FLAG immunostaining relative to eGFP fluorescence in individual
injected neurons (Figure 3) was quantified using ImageJ software.
Images were captured for analysis using identical microscope
settings between samples for each channel. Time-lapse images of
Nmnat2-eGFP transport were acquired 6 h after injection of the
expression vector using an Olympus Cell
R imaging system
comprising IX81 microscope linked to a Hamamatsu ORCA
ER camera and a 10061.45 NA apochromat objective. Cultures
were maintained at 37uC in a Solent Scientific environment
chamber. Wide-field epifluorescence images were captured at
2 Hz for 1 min. ImageJ software plug-ins were used for analysis of
the stacks (kymograph generation and analysis of particle
velocities) and conversion of an image stack into an annotated
movie (Video S1).
Quantification of Neurite Degeneration
Neurite blebbing. Membrane blebs more than twice the
width of the associated neurite or neurite bundle were counted in a
1006100 mm box in bright-field images of the same neurites just
after treatment (0 h) and the indicated times afterwards. Bleb
numbers are likely to be under-scored on highly degenerated
neurites due to clustering of multiple blebs that cannot easily be
individually differentiated or fragment loss. Statistical analysis was
performed using a two-tailed t test.
Degeneration of fluorescent marker-labelled neurites.
Numbers of morphologically normal and continuous Ds-Red2- or
eGFP-labelled neurites were counted in the same field of distal
neurites at various times after manipulation/injection. In siRNA
injection experiments (Figures 4 and 5) and transection experiments
(Figure 8), the percentage of healthy neurites remaining relative to
the first time point was determined. Neurites were deemed
unhealthy if they displayed abnormal morphology (including those
with multiple swellings) or had undergone fragmentation. Neurite
outgrowth still occurred from neurons injected with siControl,
siNmnat1,o rs i Nmnat3, but any neurites that grew into the
analyzed field during the time course were not counted. In each
case statistical analysis was performed using a two-tailed t test.
Supporting Information
Figure S1 Suppression of protein synthesis induces
Wallerian-like neurite degeneration in rat SCG and
mouse DRG explant cultures. Representative bright-field
images of distal neurites in (A) wild-type (Sprague Dawley) or Wld
S
transgenic rat SCG explant cultures and (B) wild-type or Wld
S
mouse DRG explant cultures each treated with 10 mM emetine.
Images were captured at the indicated times after emetine addition
and are representative of multiple fields in three independent
experiments. DRG neurites appear to be more resistant than SCG
neurites to the effects of translation inhibitors as 20 mg/ml CHX
was required to consistently induce neurite degeneration by 24 h
(unpublished data). This is consistent with DRG neurites also
undergoing Wallerian degeneration at a slower rate than SCG
neurites (compare Figure S2B with [25]).
Found at: doi:10.1371/journal.pbio.1000300.s001 (1.78 MB TIF)
Figure S2 Neither Wld
S-mediated protection of tran-
sected SCG neurites nor Wallerian degeneration itself
requires localized translation in neurites. Representative
bright-field images of transected neurites from (A) Wld
S or (B)
wild-type (BL/6) mouse SCG explant cultures treated with
vehicle (untreated), 1 mg/ml CHX, or 10 mM emetine. Inhibitors
were added just before transection and images captured at the
times indicated after cut. Part of the cut site is visible in the
bottom left-hand corner. Increased magnification of framed
regions is shown for better visualization of neurites. Healthy-
looking Wld
S neurites occasionally detached from the culture dish
prior to 72 h after cut probably due to handling of the cultures.
Images are representative of multiple fields in two or more
independent experiments.
Found at: doi:10.1371/journal.pbio.1000300.s002 (4.79 MB TIF)
Figure S3 RT-PCR analysis indicates that mRNAs of all
three Nmnat isoforms are expressed in SCG neurons.
Amplification products were resolved on a 2% ethidium bromide-
stained agarose gel. The image is representative of three
independent experiments. Reactions with no reverse transcriptase
(no RT) were included to confirm no DNA contamination. The
amplification kinetics of each set of primers are approximately
equivalent (unpublished data), suggesting that Nmnat2 mRNA may
be expressed at slightly higher levels than Nmnat1 and Nmnat3
mRNAs.
Found at: doi:10.1371/journal.pbio.1000300.s003 (0.07 MB TIF)
Figure S4 Microinjection-based strategy for assessing
the effects of siRNAs in SCG neurons. Nuclei were injected
with a mix containing siRNA (here injected with siControl) and
pDsRed2-N1 (50 ng/ml). High expression of DsRed2 allowed clear
visualization of injected neurons and complete neurite projections
24 h after injection. The intensity of DsRed2-labeling increases
over subsequent days. A line of neuronal cell bodies was injected to
simplify differentiation of the proximal and distal portions of
neurites. Distal neurites were imaged to allow their health to be
monitored 24, 48, and 72 h after injection.
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Figure S5 Neurite degeneration triggered by Nmnat2
siRNA is a result of Nmnat2 knock-down rather than an
off-target effect. (A) Effects of the four siRNAs making up the
siNmnat2 pool – J-059190-09, -10, -11, and -12—injected
individually or in subpools (together with pDsRed2-N1 at
50 ng/ml). Neurite survival is shown as a percentage of the total
number of DsRed2-labeled neurites (healthy and abnormal) at
24 h and was quantified from three independent experiments
combining data from multiple fields (error bars=6S.E.M.). J-
059190-11 alone (100 ng/ml) and J-059190-10 and J-059190-12
in combination (50 ng/ml each) caused significant loss of distal
neurites comparable to the siNmnat2 pool (**p,0.01, ***p,0.001,
t test versus equivalent time point for siControl). J-059190-09, -10,
and -12 caused only limited neurite degeneration individually
(unpublished data). J-059190-09 injected at 25 ng/ml, equivalent
to its contribution in the siNmnat2 pool (at 100 ng/ml), also caused
significant neurite loss (*p,0.05, t test versus equivalent time
point for siControl), but this was significantly reduced compared to
injection at 100 ng/ml(
1p,0.05,
11p,0.01, t test J-059190-11 at
25 ng/ml versus 100 ng/ml at equivalent time points). (B)
Representative fluorescent images of DsRed2-labeled neurites of
wild-type (BL/6) SCG neurons 24 and 72 h after injection with J-
059190-11 or J-059190-10+-12 (together with pDsRed2-N1).
Abnormal neurite morphology and neurite loss at 72 h is
identical to that seen following injection of the siNmnat2 pool
(Figure 4).
Found at: doi:10.1371/journal.pbio.1000300.s005 (0.56 MB TIF)
Figure S6 Loss of neuron viability after injection with
siRNA and the DsRed2 expression vector at high
concentration. (A–D) Quantification of neuron viability
matched to the analyses of neurite survival in Figure 4 and
Figure S5 as indicated. The number of neurons with normal gross
morphology remaining at each time point is shown as a
percentage of those present at 24 h (error bars=6S.E.M.).
Injection of siNmnat2 appeared to cause a decrease in neuronal
viability relative to siControl in some experiments (A–C) and this
was prevented in Wld
S neurons (C). Individual siRNAs from the
siNmnat2 pool had equivalent effects on neuronal viability (D). (E)
Neuron viability was scored based on gross morphology (in
bright-field and DsRed2 imaging) of the injected neuron cell
bodies. Two of the three injected neurons shown with normal
morphology in the top panel appear abnormal 24 h later
(arrowheads, bottom panel). Assessment based on gross morphol-
ogy closely matches other indicators of cell viability (see
Figure 5B). (F) Comparison between the amounts of neuron
and neurite loss induced by siNmnat2. Percentages of viable
neurons and healthy neurites at each time point after siNmnat2
injection were normalized to matched siControl percentages in all
paired experiments performed (n=8) and are expressed as a
fraction of siControl values (error bars=6S.E.M). The significant
reduction in neurite health following injection of siNmnat2 is
proportionately far greater than the small but significant
reduction in neuronal viability (*p,0.05, ***p,0.001, t test
siNmnat2 versus siControl at equivalent time points;
111p,0.001, t
test siNmnat2 neurite survival versus siNmnat2 neuron survival at
equivalent time points). In contrast, neuron loss exceeds neurite
degeneration with all other siRNA pools. This is presumably due
to preferential loss of neurons that do not project neurites into
areas where degeneration is assessed. This may be because
neurons with shorter neurites are more susceptible to the DsRed2
toxicity that causes background cell death in these experiments
(see main text).
Found at: doi:10.1371/journal.pbio.1000300.s006 (0.83 MB TIF)
Figure S7 Wild-type SCG neurites become committed to
degenerate after approximately 6 h of protein synthesis
suppression and this is delayed by Wld
S. Representative
bright-field images of distal neurites from (A) wild-type (BL/6) or
(B) Wld
S mouse SCG explant cultures treated with 1 mg/ml CHX
for 4, 8, or 24 h before inhibitor removal. Images of the same field
of neurites were captured at the indicated times after initial
addition of the inhibitor (0 h). Framed regions are magnified for
better visualization of neurite morphology. A dashed white line
provides a reference point against which relative neurite extension
can be assessed. Images for the 4 h and 8 h treatments of BL/6
cultures are representative of nine fields in three independent
experiments, and images for the 24 h treatment of Wld
S cultures
are representative of 8 out of 10 fields in four independent
experiments. An intermediate 6 h treatment of BL/6 neurites
resulted in a mixed outcome; neurites became significantly
blebbed by 24 h in four out of nine fields in three independent
experiments. A 48 h treatment of Wld
S cultures blocked neurite
outgrowth in all six fields in three independent experiments and
caused blebbing by day 9 in four out of six fields (unpublished
data).
Found at: doi:10.1371/journal.pbio.1000300.s007 (2.96 MB TIF)
Figure S8 Wld
S levels are only slightly reduced in Wld
S
neurites 48 h after transection. Representative immunoblot
showing levels of Wld
S in transected Wld
S neurites just after cut
(0 h) and 48 h later. ß-Tubulin acts as a loading control. Absence
of the 16 kDa core Histones band in neurite extracts confirms
there is no detectable contamination with SCG cell bodies or non-
neuronal cells. Each lane represents material collected from SCG
explant cultures derived from 8–10 ganglia (below the threshold
for consistent detection of Nmnat2). Wld
S band intensity at 48 h is
plotted (centre) as a fraction of that at 0 h after normalization to ß-
Tubulin and was quantified from three independent experiments
(error bars=6S.E.M.). Images of the same field of neurites (right)
show representative transected neurite morphology at 0 h and
48 h.
Found at: doi:10.1371/journal.pbio.1000300.s008 (0.36 MB TIF)
Figure S9 Assessing injury-induced degeneration of
DsRed2-labeled SCG neurites. Representative fluorescent
images of the same field of transected DsRed2-labeled neurites of
wild-type (BL/6) neurons injected with 1 ng/ml empty FLAG
vector (FLAG-empty) and pDsRed2-N1 (50 ng/ml) immediately
after cut (0 h) and 24 h later. Lower magnification images show a
line of injected neuronal cell bodies and the neurite network
projecting from them. This pattern of injection facilitated
transection such that all injected neurons and their proximal
neurites were located on the opposite side of the cut to the
transected distal neurites. The location of the cut site is indicated.
All neurites disconnected from their cell bodies have degenerated
by 24 h. Identical results were obtained with 50 ng/ml FLAG-
empty. Increased magnification of the framed regions is shown for
better visualization of neurites.
Found at: doi:10.1371/journal.pbio.1000300.s009 (0.85 MB TIF)
Video S1 Time-lapse imaging of Nmnat2-eGFP trans-
port in SCG neurites. SCG neurons were injected with the
Nmnat2-eGFP expression vector and time-lapse images captured
6 h later. The movie shows several neurites of injected neurons
that were located to the left of the imaged field. The movie is
speeded up 56and represents 1 min in real time. A counter (in s)
is shown at the top right.
Found at: doi:10.1371/journal.pbio.1000300.s010 (4.67 MB AVI)
Nmnat2 Is Required for Axon Survival
PLoS Biology | www.plosbiology.org 16 January 2010 | Volume 8 | Issue 1 | e1000300Acknowledgments
We thank Laura Conforti, Catherine Evans, and Elisabetta Babetto for
helpful discussion and Len Stephens for the loan of microinjection
equipment.
Author Contributions
The author(s) have made the following declarations about their
contributions: Conceived and designed the experiments: JG MPC.
Performed the experiments: JG. Analyzed the data: JG. Wrote the paper:
JG MPC.
References
1. Araki T, Sasaki Y, Milbrandt J (2004) Increased nuclear NAD biosynthesis and
SIRT1 activation prevent axonal degeneration. Science 305: 1010–1013.
2. Avery MA, Sheehan AE, Kerr KS, Wang J, Freeman MR (2009) Wld
S requires
Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian
degeneration. J Cell Biol 184: 501–513.
3. Beirowski B, Babetto E, Gilley J, Mazzola F, Conforti L, et al. (2009) Non-
nuclear Wld
S determines its neuroprotective efficacy for axons and synapses in
vivo. J Neurosci 29: 653–668.
4. Conforti L, Fang G, Beirowski B, Wang MS, Sorci L, et al. (2007) NAD(+)a n d
axon degeneration revisited: Nmnat1 cannot substitute for Wld
S to delay
Wallerian degeneration. Cell Death Differ 14: 116–127.
5. Conforti L, Wilbrey A, Morreale G, Janeckova L, Beirowski B, et al. (2009) Wld
S
protein requires Nmnat activity and a short N-terminal sequence to protect
axons in mice. J Cell Biol 184: 491–500.
6. Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, et al. (2001) Wallerian
degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat
chimeric gene. Nat Neurosci 4: 1199–1206.
7. Sasaki Y, Vohra BP, Baloh RH, Milbrandt J (2009) Transgenic mice expressing
the Nmnat1 protein manifest robust delay in axonal degeneration in vivo.
J Neurosci 29: 6526–6534.
8. Yahata N, Yuasa S, Araki T (2009) Nicotinamide mononucleotide adenylyl-
transferase expression in mitochondrial matrix delays Wallerian degeneration.
J Neurosci 29: 6276–6284.
9. Chevalier-Larsen E, Holzbaur EL (2006) Axonal transport and neurodegener-
ative disease. Biochim Biophys Acta 1762: 1094–1108.
10. Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annuar A, et al.
(2003) Mutations in dynein link motor neuron degeneration to defects in
retrograde transport. Science 300: 808–812.
11. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, et al. (2003) Mutant
dynactin in motor neuron disease. Nat Genet 33: 455–456.
12. Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, et al. (2002) A kinesin
heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10).
Am J Hum Genet 71: 1189–1194.
13. Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, et al. (2001) Charcot-
Marie-Tooth disease type 2A caused by mutation in a microtubule motor
KIF1Bbeta. Cell 105: 587–597.
14. Lubinska L (1977) Early course of Wallerian degeneration in myelinated fibres of
the rat phrenic nerve. Brain Res 130: 47–63.
15. Beirowski B, Berek L, Adalbert R, Wagner D, Grumme DS, et al. (2004)
Quantitative and qualitative analysis of Wallerian degeneration using restricted
axonal labelling in YFP-H mice. J Neurosci Methods 134: 23–35.
16. MacInnis BL, Campenot RB (2005) Regulation of Wallerian degeneration and
nerve growth factor withdrawal-induced pruning of axons of sympathetic
neurons by the proteasome and the MEK/Erk pathway. Mol Cell Neurosci 28:
430–439.
17. Tsao JW, George EB, Griffin JW (1999) Temperature modulation reveals three
distinct stages of Wallerian degeneration. J Neurosci 19: 4718–4726.
18. Zhai Q, Wang J, Kim A, Liu Q, Watts R, et al. (2003) Involvement of the
ubiquitin-proteasome system in the early stages of Wallerian degeneration.
Neuron 39: 217–225.
19. Beirowski B, Adalbert R, Wagner D, Grumme DS, Addicks K, et al. (2005) The
progressive nature of Wallerian degeneration in wild-type and slow Wallerian
degeneration (Wld
S) nerves. BMC Neurosci 6: 6.
20. Kerschensteiner M, Schwab ME, Lichtman JW, Misgeld T (2005) In vivo
imaging of axonal degeneration and regeneration in the injured spinal cord. Nat
Med 11: 572–577.
21. Conforti L, Tarlton A, Mack TG, Mi W, Buckmaster EA, et al. (2000) A Ufd2/
D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian
degeneration (Wld
S) mouse. Proc Natl Acad Sci U S A 97: 11377–11382.
22. Emanuelli M, Carnevali F, Saccucci F, Pierella F, Amici A, et al. (2001)
Molecular cloning, chromosomal localization, tissue mRNA levels, bacterial
expression, and enzymatic properties of human NMN adenylyltransferase. J Biol
Chem 276: 406–412.
23. Raffaelli N, Sorci L, Amici A, Emanuelli M, Mazzola F, et al. (2002)
Identification of a novel human nicotinamide mononucleotide adenylyltransfer-
ase. Biochem Biophys Res Commun 297: 835–840.
24. Zhang X, Kurnasov OV, Karthikeyan S, Grishin NV, Osterman AL, et al.
(2003) Structural characterization of a human cytosolic NMN/NaMN
adenylyltransferase and implication in human NAD biosynthesis. J Biol Chem
278: 13503–13511.
25. Sasaki Y, Araki T, Milbrandt J (2006) Stimulation of nicotinamide adenine
dinucleotide biosynthetic pathways delays axonal degeneration after axotomy.
J Neurosci 26: 8484–8491.
26. Yan T, Feng Y, Zheng J, Ge X, Zhang Y, et al. (2009) Nmnat2 delays axon
degeneration in superior cervical ganglia dependent on its NAD synthesis
activity. Neurochem Int Epub ahead of print.
27. Ferri A, Sanes JR, Coleman MP, Cunningham JM, Kato AC (2003) Inhibiting
axon degeneration and synapse loss attenuates apoptosis and disease progression
in a mouse model of motoneuron disease. Curr Biol 13: 669–673.
28. Wang M, Wu Y, Culver DG, Glass JD (2001) The gene for slow Wallerian
degeneration (Wld
S) is also protective against vincristine neuropathy. Neurobiol
Dis 8: 155–161.
29. Martin DP, Ito A, Horigome K, Lampe PA, Johnson EM Jr (1992) Biochemical
characterization of programmed cell death in NGF-deprived sympathetic
neurons. J Neurobiol 23: 1205–1220.
30. Kirkland RA, Franklin JL (2007) Rate of neurite outgrowth in sympathetic
neurons is highly resistant to suppression of protein synthesis: role of protein
degradation/synthesis coupling. Neurosci Lett 411: 52–55.
31. Estridge M, Bunge R (1978) Compositional analysis of growing axons from rat
sympathetic neurons. J Cell Biol 79: 138–155.
32. Fainzilber M, Twiss JL (2006) Tracking in the Wld
S - the hunting of the SIRT
and the luring of the Draper. Neuron 50: 819–821.
33. Eng H, Lund K, Campenot RB (1999) Synthesis of beta-tubulin, actin, and
other proteins in axons of sympathetic neurons in compartmented cultures.
J Neurosci 19: 1–9.
34. Berger F, Lau C, Dahlmann M, Ziegler M (2005) Subcellular compartmentation
and differential catalytic properties of the three human nicotinamide
mononucleotide adenylyltransferase isoforms. J Biol Chem 280: 36334–36341.
35. Deckwerth TL, Johnson EM, Jr. (1994) Neurites can remain viable after
destruction of the neuronal soma by programmed cell death (apoptosis). Dev
Biol 165: 63–72.
36. Burne JF, Staple JK, Raff MC (1996) Glial cells are increased proportionally in
transgenic optic nerves with increased numbers of axons. J Neurosci 16:
2064–2073.
37. Finn JT, Weil M, Archer F, Siman R, Srinivasan A, et al. (2000) Evidence that
Wallerian degeneration and localized axon degeneration induced by local
neurotrophin deprivation do not involve caspases. J Neurosci 20: 1333–1341.
38. Whitmore AV, Lindsten T, Raff MC, Thompson CB (2003) The proapoptotic
proteins Bax and Bak are not involved in Wallerian degeneration. Cell Death
Differ 10: 260–261.
39. Laser H, Mack TG, Wagner D, Coleman MP (2003) Proteasome inhibition
arrests neurite outgrowth and causes ‘‘dying-back’’ degeneration in primary
culture. J Neurosci Res 74: 906–916.
40. Lunn ER, Perry VH, Brown MC, Rosen H, Gordon S (1989) Absence of
Wallerian degeneration does not hinder regeneration in peripheral nerve.
Eur J Neurosci 1: 27–33.
41. Wang MS, Davis AA, Culver DG, Glass JD (2002) Wld
S mice are resistant to
paclitaxel (taxol) neuropathy. Ann Neurol 52: 442–447.
42. Merianda TT, Lin AC, Lam JS, Vuppalanchi D, Willis DE, et al. (2008) A
functional equivalent of endoplasmic reticulum and Golgi in axons for secretion
of locally synthesized proteins. Mol Cell Neurosci.
43. Sasaki Y, Vohra BP, Lund FE, Milbrandt J (2009) Nicotinamide mononucle-
otide adenylyl transferase-mediated axonal protection requires enzymatic
activity but not increased levels of neuronal nicotinamide adenine dinucleotide.
J Neurosci 29: 5525–5535.
44. Suzuki K, Koike T (2007) Resveratrol abolishes resistance to axonal
degeneration in slow Wallerian degeneration (Wld
S) mice: activation of SIRT2,
an NAD-dependent tubulin deacetylase. Biochem Biophys Res Commun 359:
665–671.
45. Wang J, Zhai Q, Chen Y, Lin E, Gu W, et al. (2005) A local mechanism
mediates NAD-dependent protection of axon degeneration. J Cell Biol 170:
349–355.
46. Miller BR, Press C, Daniels RW, Sasaki Y, Milbrandt J, et al. (2009) A dual
leucine kinase-dependent axon self-destruction program promotes Wallerian
degeneration. Nat Neurosci 12: 387–389.
47. Spencer MJ, Guyon JR, Sorimachi H, Potts A, Richard I, et al. (2002) Stable
expression of calpain 3 from a muscle transgene in vivo: immature muscle in
transgenic mice suggests a role for calpain 3 in muscle maturation. Proc Natl
Acad Sci U S A 99: 8874–8879.
48. Zhai RG, Cao Y, Hiesinger PR, Zhou Y, Mehta SQ, et al. (2006) Drosophila
NMNAT maintains neural integrity independent of its NAD synthesis activity.
PLoS Biol 4: e416. doi:10.1371/journal.pbio.0040416.
49. Zhai RG, Zhang F, Hiesinger PR, Cao Y, Haueter CM, et al. (2008) NAD
synthase NMNAT acts as a chaperone to protect against neurodegeneration.
Nature 452: 887–891.
50. De Vos KJ, Grierson AJ, Ackerley S, Miller CC (2008) Role of axonal transport
in neurodegenerative diseases. Annu Rev Neurosci 31: 151–173.
Nmnat2 Is Required for Axon Survival
PLoS Biology | www.plosbiology.org 17 January 2010 | Volume 8 | Issue 1 | e100030051. Minoshima S, Cross D (2008) In vivo imaging of axonal transport using MRI:
aging and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35 Suppl 1:
S89–S92.
52. Wong ML, Yen YR (1998) Protein synthesis in pseudorabies virus-infected cells:
decreased expression of protein kinase PKR, and effects of 2-aminopurine and
adenine. Virus Res 56: 199–206.
53. Bendotti C, Calvaresi N, Chiveri L, Prelle A, Moggio M, et al. (2001) Early
vacuolization and mitochondrial damage in motor neurons of FALS mice are
not associated with apoptosis or with changes in cytochrome oxidase
histochemical reactivity. J Neurol Sci 191: 25–33.
54. Fischer LR, Culver DG, Davis AA, Tennant P, Wang M, et al. (2005) The Wld
S
gene modestly prolongs survival in the SOD1G93A fALS mouse. Neurobiol Dis
19: 293–300.
55. Campenot RB (1992) Construction and use of compartmented cultures.
Protocols for Neural Cell Culture: Humana Press Inc. pp 53–63.
56. Adalbert R, Gillingwater TH, Haley JE, Bridge K, Beirowski B, et al. (2005) A
rat model of slow Wallerian degeneration (WldS) with improved preservation of
neuromuscular synapses. Eur J Neurosci 21: 271–277.
Nmnat2 Is Required for Axon Survival
PLoS Biology | www.plosbiology.org 18 January 2010 | Volume 8 | Issue 1 | e1000300